SI3224254T1 - Substituirani indazoli, postopek njihove priprave, farmacevtske formulacije, ki jih vsebujejo in njihova uporaba za pripravo zdravil - Google Patents

Substituirani indazoli, postopek njihove priprave, farmacevtske formulacije, ki jih vsebujejo in njihova uporaba za pripravo zdravil

Info

Publication number
SI3224254T1
SI3224254T1 SI201531182T SI201531182T SI3224254T1 SI 3224254 T1 SI3224254 T1 SI 3224254T1 SI 201531182 T SI201531182 T SI 201531182T SI 201531182 T SI201531182 T SI 201531182T SI 3224254 T1 SI3224254 T1 SI 3224254T1
Authority
SI
Slovenia
Prior art keywords
preparation
medicaments
pharmaceutical formulations
formulations containing
substituted indazoles
Prior art date
Application number
SI201531182T
Other languages
English (en)
Inventor
Ulrich Bothe
Holger Siebeneicher
Nicole Schmidt
Reinhard Nubbemeyer
Ulf Bomer
Judith Gunther
Holger Steuber
Martin Lange
Christian Stegmann
Andreas Sutter
Alexandra Rausch
Peter Hauff
Christian Friedrich
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of SI3224254T1 publication Critical patent/SI3224254T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201531182T 2014-11-26 2015-11-25 Substituirani indazoli, postopek njihove priprave, farmacevtske formulacije, ki jih vsebujejo in njihova uporaba za pripravo zdravil SI3224254T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26
PCT/EP2015/077596 WO2016083433A1 (de) 2014-11-26 2015-11-25 Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln
EP15800828.4A EP3224254B1 (de) 2014-11-26 2015-11-25 Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
SI3224254T1 true SI3224254T1 (sl) 2020-07-31

Family

ID=51982455

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201532005T SI3674298T1 (sl) 2014-11-26 2015-11-25 Substituirani indazoli, postopek za njihovo pripravo, farmacevtske formulacije, ki jih vsebujejo, in njihova uporaba za pripravo zdravil
SI201531182T SI3224254T1 (sl) 2014-11-26 2015-11-25 Substituirani indazoli, postopek njihove priprave, farmacevtske formulacije, ki jih vsebujejo in njihova uporaba za pripravo zdravil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201532005T SI3674298T1 (sl) 2014-11-26 2015-11-25 Substituirani indazoli, postopek za njihovo pripravo, farmacevtske formulacije, ki jih vsebujejo, in njihova uporaba za pripravo zdravil

Country Status (42)

Country Link
US (5) US10308634B2 (sl)
EP (3) EP4260909A3 (sl)
JP (1) JP6496823B2 (sl)
KR (1) KR102083857B1 (sl)
CN (2) CN107406416B (sl)
AR (1) AR102827A1 (sl)
AU (2) AU2015352603B2 (sl)
BR (2) BR112017011005B1 (sl)
CA (1) CA2968614C (sl)
CL (1) CL2017001364A1 (sl)
CO (1) CO2017005374A2 (sl)
CR (1) CR20170220A (sl)
CU (1) CU24448B1 (sl)
CY (1) CY1123815T1 (sl)
DK (2) DK3674298T3 (sl)
DO (1) DOP2017000127A (sl)
EA (1) EA032509B1 (sl)
EC (1) ECSP17032530A (sl)
ES (2) ES2976932T3 (sl)
FI (1) FI3674298T3 (sl)
HR (2) HRP20240414T1 (sl)
HU (2) HUE065938T2 (sl)
IL (3) IL252185B (sl)
JO (1) JO3705B1 (sl)
LT (2) LT3674298T (sl)
MA (1) MA41011B1 (sl)
ME (1) ME03745B (sl)
MX (2) MX2017006910A (sl)
NI (1) NI201700063A (sl)
NZ (1) NZ732126A (sl)
PE (1) PE20171376A1 (sl)
PH (1) PH12017500972A1 (sl)
PL (2) PL3674298T3 (sl)
PT (2) PT3224254T (sl)
RS (2) RS65327B1 (sl)
SG (3) SG11201704092YA (sl)
SI (2) SI3674298T1 (sl)
TN (1) TN2017000226A1 (sl)
TW (2) TWI689502B (sl)
UA (2) UA123813C2 (sl)
UY (1) UY36411A (sl)
WO (1) WO2016083433A1 (sl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935880A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
BR112016016158B1 (pt) 2014-01-13 2022-12-13 Aurigene Discovery Technologies Limited Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3195865A1 (de) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
GEP20217214B (en) * 2016-04-29 2021-01-25 Bayer Pharma AG Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
CN109071491B (zh) * 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
EA035867B1 (ru) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Синтез индазолов
EA201892790A1 (ru) 2016-06-01 2019-06-28 Байер Фарма Акциенгезельшафт Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
KR102547834B1 (ko) * 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
FI3600270T3 (fi) 2017-03-31 2023-07-20 Aurigene Oncology Ltd Yhdisteitä ja koostumuksia hematologisten häiriöiden hoitoon
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
AU2018317403B2 (en) 2017-08-16 2023-09-21 Vanderbilt University Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
EP3814329B1 (en) 2018-06-27 2024-01-17 F. Hoffmann-La Roche AG Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11897863B2 (en) 2018-08-17 2024-02-13 Zhejiang Hisun Pharmaceutical Co., Ltd. Indazole amine derivative, preparation method therefor and medical use thereof
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
EP3889150A4 (en) * 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. IRAQ INHIBITOR COMPOUND
CN111362920B (zh) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN111560012B (zh) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
WO2020259626A1 (zh) * 2019-06-26 2020-12-30 南京明德新药研发有限公司 作为irak4抑制剂的咪唑并吡啶类化合物
EP3990432A1 (en) * 2019-06-27 2022-05-04 Biogen MA Inc. 2h-indazole derivatives and their use in the treatment of disease
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
PE20220944A1 (es) * 2019-09-24 2022-05-31 Shanghai Meiyue Biotech Dev Co Ltd Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
CN113278017B (zh) * 2021-05-27 2023-03-28 上海应用技术大学 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
JP2024525580A (ja) * 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途
WO2024108010A1 (en) * 2022-11-17 2024-05-23 Bayer Animal Health Gmbh Methods and compositions for control of pain and inflammation
CN116120283A (zh) * 2022-12-13 2023-05-16 药康众拓(北京)医药科技有限公司 一种氘代啶酰胺类irak-4抑制剂药物及用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
JP4777648B2 (ja) * 2002-07-31 2011-09-21 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｖｅｇｆｒ−２及びｖｅｇｆｒ−３阻害性アントラニルアミドピリジン
DK1646608T3 (da) 2003-06-25 2011-06-14 Je Il Pharmaceutical Co Ltd Tricykliske derivater eller farmaceutisk acceptable salte deraf, deres fremstillinger og farmaceutiske sammensætninger indeholdende dem
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
US20080161365A1 (en) 2004-12-08 2008-07-03 Pfizer Inc. Methylene Derivatives
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
EP1986643A1 (en) 2006-02-10 2008-11-05 Summit Corporation Plc Treatment of duchenne muscular dystrophy
TWI435863B (zh) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
WO2008030584A2 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
US9073892B2 (en) * 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
ES2591129T3 (es) 2012-05-21 2016-11-25 Bayer Pharma Aktiengesellschaft Tienopirimidinas
JP2015002717A (ja) 2013-06-21 2015-01-08 住友ベークライト株式会社 蓋付き容器
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
CA2935880A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
US20170152263A1 (en) 2014-06-20 2017-06-01 Aurigene Discovery Technologies Limited Substituted Indazole Compounds as IRAK4 Inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
WO2017009798A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
GEP20217214B (en) 2016-04-29 2021-01-25 Bayer Pharma AG Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
EA201892790A1 (ru) 2016-06-01 2019-06-28 Байер Фарма Акциенгезельшафт Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
KR102547834B1 (ko) 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸

Also Published As

Publication number Publication date
AR102827A1 (es) 2017-03-29
HRP20240414T1 (hr) 2024-06-21
AU2020200979B2 (en) 2021-01-07
AU2020200979A1 (en) 2020-02-27
UA123813C2 (uk) 2021-06-02
EP3674298B9 (de) 2024-06-19
ES2796285T3 (es) 2020-11-26
US12006304B2 (en) 2024-06-11
TW202002973A (zh) 2020-01-16
SG10201903474PA (en) 2019-05-30
CA2968614A1 (en) 2016-06-02
TN2017000226A1 (en) 2018-10-19
US20230174508A1 (en) 2023-06-08
IL269444B (en) 2020-07-30
US20190233395A1 (en) 2019-08-01
IL269444A (en) 2019-11-28
CA2968614C (en) 2019-10-29
BR112017011005B1 (pt) 2023-03-14
CN110305109A (zh) 2019-10-08
CU24448B1 (es) 2019-10-04
IL252185A0 (en) 2017-07-31
EP4260909A3 (de) 2024-03-20
SG10201903475TA (en) 2019-05-30
KR20170085590A (ko) 2017-07-24
NI201700063A (es) 2017-07-17
ECSP17032530A (es) 2017-06-30
UA120948C2 (uk) 2020-03-10
IL267537A (en) 2019-08-29
EP3224254B1 (de) 2020-04-15
HUE065938T2 (hu) 2024-06-28
EA032509B1 (ru) 2019-06-28
CN107406416B (zh) 2020-04-21
FI3674298T3 (fi) 2024-04-17
EP4260909A2 (de) 2023-10-18
US20220388982A1 (en) 2022-12-08
EP3674298B1 (de) 2024-01-10
DK3674298T3 (da) 2024-04-08
CY1123815T1 (el) 2022-03-24
SI3674298T1 (sl) 2024-05-31
PT3674298T (pt) 2024-04-01
TWI689502B (zh) 2020-04-01
TW201629037A (zh) 2016-08-16
WO2016083433A1 (de) 2016-06-02
US10308634B2 (en) 2019-06-04
JP2017535585A (ja) 2017-11-30
LT3674298T (lt) 2024-04-10
ES2976932T3 (es) 2024-08-13
HRP20200974T1 (hr) 2020-10-02
CN110305109B (zh) 2022-04-08
US10793545B2 (en) 2020-10-06
MX2020010623A (es) 2022-02-16
US20170349570A1 (en) 2017-12-07
CO2017005374A2 (es) 2017-08-31
RS60284B1 (sr) 2020-06-30
SG11201704092YA (en) 2017-06-29
EP3224254A1 (de) 2017-10-04
NZ732126A (en) 2018-09-28
PE20171376A1 (es) 2017-09-15
PH12017500972A1 (en) 2017-12-18
CN107406416A (zh) 2017-11-28
JP6496823B2 (ja) 2019-04-10
AU2015352603B2 (en) 2020-04-02
KR102083857B1 (ko) 2020-03-03
PT3224254T (pt) 2020-06-17
UY36411A (es) 2016-06-30
HUE049341T2 (hu) 2020-09-28
LT3224254T (lt) 2020-06-10
MA41011B1 (fr) 2020-08-31
IL267537B (en) 2020-07-30
TWI717061B (zh) 2021-01-21
RS65327B1 (sr) 2024-04-30
JO3705B1 (ar) 2021-01-31
CR20170220A (es) 2017-10-31
AU2015352603A1 (en) 2017-06-01
PL3224254T3 (pl) 2020-09-21
ME03745B (me) 2021-04-20
EA201791137A1 (ru) 2017-11-30
ES2976932T9 (es) 2024-09-05
BR112017011005A2 (pt) 2019-05-14
BR122021002613B1 (pt) 2023-04-11
US20210053941A1 (en) 2021-02-25
US12006303B2 (en) 2024-06-11
EP3674298A1 (de) 2020-07-01
CU20170073A7 (es) 2017-10-05
DK3224254T3 (da) 2020-07-13
CL2017001364A1 (es) 2017-12-15
DOP2017000127A (es) 2017-07-31
PL3674298T3 (pl) 2024-06-24
IL252185B (en) 2019-10-31
MX2017006910A (es) 2017-08-15

Similar Documents

Publication Publication Date Title
LT3674298T (lt) Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
IL251302B (en) History of boronic acid, their preparation and medicines containing them
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
IL251299A0 (en) History of boronic acid, their preparation and medicines containing them
IL251300A0 (en) History of boronic acid, their preparation and medicines containing them
IL251301A0 (en) History of boronic acid, their preparation and medicines containing them
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IL250267A0 (en) History of indolizine, their preparation and pharmaceutical preparations containing them
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
IL249308B (en) The history of quinoline, their preparation and pharmaceutical preparations containing them
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
HK1257129A1 (zh) 含有吲哚衍生物的藥物組合物、其製備方法和用途
PT2957280T (pt) Composição farmacêutica sólida de citisina e processo para a sua preparação
PL2996675T3 (pl) Formulacja farmaceutyczna, sposób wytwarzania formulacji farmaceutycznej i roztwór do infuzji oraz ich zastosowanie jako wyrobu medycznego i/lub leku
HUP1400084A2 (hu) Dabigatran és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói